key: cord-0700106-etmohtjp
authors: Ramadan, Leena; Koziatek, Christian A.; Caldwell, J. Reed; Pecoriello, Jillian; Kuhner, Christopher; Subaiya, Saleena; Lee, David C.
title: Pulmonary thromboembolism in COVID-19: Evaluating the role of D-dimer and computed tomography pulmonary angiography results
date: 2020-09-05
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.08.096
sha: ac4b225a1097b4482d5db52a95afcaf25580a474
doc_id: 700106
cord_uid: etmohtjp

nan

Pulmonary thromboembolism in COVID-19: Evaluating the role of D-dimer and computed tomography pulmonary angiography results COVID-19 patients have a strong propensity to develop thrombosis and their respiratory symptoms often prompt clinicians to assess for the presence of a pulmonary thromboembolism (PTE) [1, 2] . Prior research estimates that approximately 20% to 30% of patients with COVID-19 have a PTE demonstrated by computed tomography pulmonary angiography (CTPA) [3, 4] . Some clinical decision rules such as the Pulmonary Embolism Rule-Out Criteria (PERC) and Wells' Criteria are used to assess a patient's risk of PTE. However, patients with COVID-19 can present with chest pain, tachycardia, tachypnea, and hypoxia even without a PTE; therefore, many of these clinical decisionmaking tools are unhelpful. Furthermore, elevations of d-dimer are frequent in COVID-19 given the pathophysiology of the disease. Recent studies have explored using higher thresholds for d-dimer testing among COVID-19 patients (e.g., from 2000 μg/L to 4000 μg/L) [5] . However, it is not clear that these are appropriate parameters based on their sensitivity and specificity [5, 6] .

We performed a retrospective cohort study at our hospitals in the NYU Langone Health System across Manhattan, Brooklyn and Long Island to evaluate the sensitivity and specificity of d-dimer testing to diagnose PTE among COVID-19 patients. We specifically compared CTPA studies performed in the emergency department (ED) versus those performed in the inpatient setting since d-dimer can increase during hospitalization due to disease progression [7] . From March 1, 2020 to June 1st, 2020, a total of 367 admitted COVID-19 positive patients had a CTPA study, as described in Table 1 . Of these studies 157 (43%) were performed within 6 h of their arrival in the ED, and 210 (57%) were completed later during their inpatient hospitalization. Forty-five (29%) of the emergency department (ED) patients and 52 (25%) of the inpatients were diagnosed with an identifiable PTE.

We also compared the sensitivity and specificity of d-dimer levels drawn within 6 h of arrival for CTPA studies performed in the ED (139 of 157 ED patients) or within 48 h of inpatient CTPA studies (165 of 210 inpatients) to predict the presence of a PTE (Fig. 1) . At a cutoff of 2000 μg/L (i.e., eight times the normal limit of 250 μg/L), a d-dimer test would have a 78% sensitivity and 67% specificity for an identifiable PTE in the ED and a 63% sensitivity and 66% specificity in the inpatient setting among patients who received a CTPA in our study. Even if we used a cutoff at just two times the normal limit (i.e., 500 μg/L), a d-dimer only had a 94% sensitivity and 30% specificity for an identifiable PTE in the ED, compared to a sensitivity of 89% and specificity of 23% in the inpatient setting. We should point out that this study is limited by its retrospective study design and reported rates of PTE may not accurately reflect the true prevalence of PTE among COVID-19 patients. Furthermore, we also noted that 31% and 40% of the ED and inpatient studies respectively were deemed to be suboptimal or inconclusive, American Journal of Emergency Medicine xxx (2020) xxx YAJEM-159364; No of Pages 2 e.g., unable to rule out a segmental or subsegmental PTE. This was largely due to motion artifact or mistimed contrast enhancement.

Our data supports the prior literature suggesting a relatively high incidence of PTE among COVID-19 patients [3, 4] . Previously, it was reported that a cutoff of 2660 μg/L was 100% sensitive for PTE [6] . However, we find that a lower threshold may be required to identify more of these events. Furthermore, we found that a given d-dimer cutoff may be more sensitive or specific for identifying PTE in the ED when compared to the inpatient setting. This finding may be explained by the ongoing inflammation and coagulopathy given that d-dimer levels increase among some patients who experience disease progression [7] .

In addition, 37% of patients in our study had a CTPA that was inconclusive for ruling out a PTE and some clots may have been missed. The actual rate of PTE among COVID-19 patients could be much higher than suggested by the rate of positive CTPA studies. It is also known, based on pathology reports, that even in the absence of a large thromboembolism identifiable by CTPA that COVID-19 patients have numerous microthrombi in their pulmonary vasculature, which is likely a critical component of the pathophysiology of the disease [8] . Given the poor sensitivity and specificity of d-dimer tests and high rate of nondiagnostic CTPA studies, the role of these diagnostic tests among COVID-19 patients should be reevaluated. Given the high risk of thromboembolism, surging COVID-19 patient volumes, and the difficulty of obtaining CTPA studies on all COVID-19 patients with an elevated d-dimer, empiric anticoagulation may be a more effective strategy than attempting to determine which patients should have a CTPA study based on any decision rule or d-dimer testing. Studies of anticoagulation are urgently needed to identify the most effective treatments to reduce morbidity and mortality of COVID-19. In these studies, laboratory markers, such as d-dimer, may help determine when to initiate or continue empiric anticoagulation.

COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands

Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-Dimer levels

D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases

United States of America Corresponding author at: 462 First Ave, Room A340A

Perelman Department of Emergency Medicine

Perelman Department of Emergency Medicine

Available online xxxx

Legend: Comparison of the sensitivity and specificity of d-dimer for COVID-19 patients with an identifiable pulmonary thromboembolism. Circles denote values at a d-dimer level of 500 μg/L